|
Gene: COX17 |
Gene summary for COX17 |
Gene summary. |
Gene information | Species | Human | Gene symbol | COX17 | Gene ID | 10063 |
Gene name | cytochrome c oxidase copper chaperone COX17 | |
Gene Alias | COX17 | |
Cytomap | 3q13.33 | |
Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | Q14061 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10063 | COX17 | C07 | Human | Oral cavity | OSCC | 7.94e-11 | 2.10e+00 | 0.2491 |
10063 | COX17 | C08 | Human | Oral cavity | OSCC | 9.65e-53 | 1.69e+00 | 0.1919 |
10063 | COX17 | C09 | Human | Oral cavity | OSCC | 2.04e-35 | 1.39e+00 | 0.1431 |
10063 | COX17 | LN22 | Human | Oral cavity | OSCC | 4.33e-19 | 2.07e+00 | 0.1733 |
10063 | COX17 | LN38 | Human | Oral cavity | OSCC | 1.12e-11 | 2.08e+00 | 0.168 |
10063 | COX17 | LN46 | Human | Oral cavity | OSCC | 2.94e-22 | 1.30e+00 | 0.1666 |
10063 | COX17 | LP15 | Human | Oral cavity | LP | 7.56e-18 | 2.58e+00 | 0.2174 |
10063 | COX17 | LP17 | Human | Oral cavity | LP | 2.39e-08 | 2.15e+00 | 0.2349 |
10063 | COX17 | SYSMH1 | Human | Oral cavity | OSCC | 7.25e-31 | 9.90e-01 | 0.1127 |
10063 | COX17 | SYSMH2 | Human | Oral cavity | OSCC | 3.49e-21 | 1.29e+00 | 0.2326 |
10063 | COX17 | SYSMH3 | Human | Oral cavity | OSCC | 2.44e-29 | 1.28e+00 | 0.2442 |
10063 | COX17 | SYSMH5 | Human | Oral cavity | OSCC | 1.67e-06 | 4.72e-01 | 0.0647 |
10063 | COX17 | SYSMH6 | Human | Oral cavity | OSCC | 1.01e-08 | 8.93e-01 | 0.1275 |
10063 | COX17 | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 2.34e-05 | 4.47e-01 | -0.1972 |
10063 | COX17 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 2.08e-02 | 3.50e-01 | -0.1833 |
10063 | COX17 | 047563_1562-all-cells | Human | Prostate | BPH | 4.78e-14 | -3.04e-01 | 0.0791 |
10063 | COX17 | 048752_1579-all-cells | Human | Prostate | BPH | 4.62e-02 | -3.18e-01 | 0.1008 |
10063 | COX17 | 052095_1628-all-cells | Human | Prostate | BPH | 2.52e-02 | -3.60e-01 | 0.1032 |
10063 | COX17 | 052097_1595-all-cells | Human | Prostate | BPH | 5.19e-05 | -3.32e-01 | 0.0972 |
10063 | COX17 | 052099_1652-all-cells | Human | Prostate | BPH | 3.35e-06 | -3.55e-01 | 0.1038 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
GO:19026008 | Breast | Precancer | proton transmembrane transport | 39/1080 | 157/18723 | 4.18e-15 | 1.18e-12 | 39 |
GO:00331088 | Breast | Precancer | mitochondrial respiratory chain complex assembly | 24/1080 | 93/18723 | 3.39e-10 | 3.16e-08 | 24 |
GO:00434677 | Breast | Precancer | regulation of generation of precursor metabolites and energy | 22/1080 | 130/18723 | 4.95e-06 | 1.51e-04 | 22 |
GO:00324116 | Breast | Precancer | positive regulation of transporter activity | 16/1080 | 120/18723 | 1.46e-03 | 1.51e-02 | 16 |
GO:00347673 | Breast | Precancer | positive regulation of ion transmembrane transport | 19/1080 | 167/18723 | 3.60e-03 | 2.98e-02 | 19 |
GO:00324143 | Breast | Precancer | positive regulation of ion transmembrane transporter activity | 14/1080 | 109/18723 | 3.97e-03 | 3.15e-02 | 14 |
GO:00228985 | Breast | Precancer | regulation of transmembrane transporter activity | 27/1080 | 278/18723 | 5.72e-03 | 4.11e-02 | 27 |
GO:00000412 | Breast | Precancer | transition metal ion transport | 13/1080 | 105/18723 | 7.35e-03 | 4.89e-02 | 13 |
GO:000609113 | Breast | IDC | generation of precursor metabolites and energy | 103/1434 | 490/18723 | 1.53e-21 | 1.74e-18 | 103 |
GO:190260012 | Breast | IDC | proton transmembrane transport | 40/1434 | 157/18723 | 7.34e-12 | 1.34e-09 | 40 |
GO:003310813 | Breast | IDC | mitochondrial respiratory chain complex assembly | 28/1434 | 93/18723 | 1.54e-10 | 1.83e-08 | 28 |
GO:004346713 | Breast | IDC | regulation of generation of precursor metabolites and energy | 23/1434 | 130/18723 | 1.29e-04 | 2.34e-03 | 23 |
GO:003241111 | Breast | IDC | positive regulation of transporter activity | 20/1434 | 120/18723 | 7.64e-04 | 9.27e-03 | 20 |
GO:00432703 | Breast | IDC | positive regulation of ion transport | 36/1434 | 275/18723 | 1.11e-03 | 1.22e-02 | 36 |
GO:002289812 | Breast | IDC | regulation of transmembrane transporter activity | 36/1434 | 278/18723 | 1.35e-03 | 1.40e-02 | 36 |
GO:003241411 | Breast | IDC | positive regulation of ion transmembrane transporter activity | 18/1434 | 109/18723 | 1.53e-03 | 1.53e-02 | 18 |
GO:003476711 | Breast | IDC | positive regulation of ion transmembrane transport | 24/1434 | 167/18723 | 2.07e-03 | 1.95e-02 | 24 |
GO:00324125 | Breast | IDC | regulation of ion transmembrane transporter activity | 33/1434 | 267/18723 | 4.38e-03 | 3.40e-02 | 33 |
GO:00324096 | Breast | IDC | regulation of transporter activity | 37/1434 | 310/18723 | 4.77e-03 | 3.66e-02 | 37 |
Page: 1 2 3 4 5 6 7 8 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0019023 | Breast | IDC | Oxidative phosphorylation | 62/867 | 134/8465 | 4.78e-27 | 2.59e-25 | 1.94e-25 | 62 |
hsa0471424 | Breast | IDC | Thermogenesis | 75/867 | 232/8465 | 8.41e-21 | 3.04e-19 | 2.27e-19 | 75 |
hsa0019033 | Breast | IDC | Oxidative phosphorylation | 62/867 | 134/8465 | 4.78e-27 | 2.59e-25 | 1.94e-25 | 62 |
hsa0471434 | Breast | IDC | Thermogenesis | 75/867 | 232/8465 | 8.41e-21 | 3.04e-19 | 2.27e-19 | 75 |
hsa0019043 | Breast | DCIS | Oxidative phosphorylation | 61/846 | 134/8465 | 9.84e-27 | 5.30e-25 | 3.90e-25 | 61 |
hsa0471443 | Breast | DCIS | Thermogenesis | 74/846 | 232/8465 | 8.72e-21 | 3.13e-19 | 2.30e-19 | 74 |
hsa0019053 | Breast | DCIS | Oxidative phosphorylation | 61/846 | 134/8465 | 9.84e-27 | 5.30e-25 | 3.90e-25 | 61 |
hsa0471453 | Breast | DCIS | Thermogenesis | 74/846 | 232/8465 | 8.72e-21 | 3.13e-19 | 2.30e-19 | 74 |
hsa0019018 | Cervix | CC | Oxidative phosphorylation | 64/1267 | 134/8465 | 1.25e-19 | 8.07e-18 | 4.77e-18 | 64 |
hsa0471420 | Cervix | CC | Thermogenesis | 76/1267 | 232/8465 | 4.29e-12 | 1.16e-10 | 6.85e-11 | 76 |
hsa0019019 | Cervix | CC | Oxidative phosphorylation | 64/1267 | 134/8465 | 1.25e-19 | 8.07e-18 | 4.77e-18 | 64 |
hsa04714110 | Cervix | CC | Thermogenesis | 76/1267 | 232/8465 | 4.29e-12 | 1.16e-10 | 6.85e-11 | 76 |
hsa00190 | Colorectum | AD | Oxidative phosphorylation | 86/2092 | 134/8465 | 2.47e-22 | 2.76e-20 | 1.76e-20 | 86 |
hsa04714 | Colorectum | AD | Thermogenesis | 120/2092 | 232/8465 | 2.76e-19 | 1.16e-17 | 7.37e-18 | 120 |
hsa001901 | Colorectum | AD | Oxidative phosphorylation | 86/2092 | 134/8465 | 2.47e-22 | 2.76e-20 | 1.76e-20 | 86 |
hsa047141 | Colorectum | AD | Thermogenesis | 120/2092 | 232/8465 | 2.76e-19 | 1.16e-17 | 7.37e-18 | 120 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
COX17 | SNV | Missense_Mutation | novel | c.100G>C | p.Asp34His | p.D34H | Q14061 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
COX17 | SNV | Missense_Mutation | novel | c.44A>G | p.Gln15Arg | p.Q15R | Q14061 | protein_coding | tolerated(0.24) | benign(0.124) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
COX17 | SNV | Missense_Mutation | novel | c.118A>G | p.Lys40Glu | p.K40E | Q14061 | protein_coding | tolerated(0.13) | possibly_damaging(0.524) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
COX17 | SNV | Missense_Mutation | c.115G>A | p.Glu39Lys | p.E39K | Q14061 | protein_coding | tolerated(0.07) | possibly_damaging(0.857) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
COX17 | SNV | Missense_Mutation | novel | c.104N>T | p.Ala35Val | p.A35V | Q14061 | protein_coding | tolerated(0.12) | benign(0.01) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
COX17 | SNV | Missense_Mutation | novel | c.10N>G | p.Leu4Val | p.L4V | Q14061 | protein_coding | tolerated(0.46) | benign(0.001) | TCGA-CR-6480-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | paclitaxel | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |